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Reocclusion of infarct-related coronary arteries within 2 weeks of
thrombolytic therapy varies from 5% to 45% and neither clinical
nor angiographic variables have been proved to be predictive of
reocclusion. The goal of the present study was to evaluate whether
aspirin could prevent coronary reocclusion and recurrent isch-
emia after thrombolysis. For this purpose, a meta.analysis includ·
ing 32 studies was performed.
Although the studies showed very similar demographic data,
the reocclusion rate assessed by angiography in 419 patients
Thrombolysis has considerably improved the treatment of
myocardial infarction (1) and has lowered the early mortality
rate to approximately 5% from the 12% rate reported before
the thrombolytic era. However, despite the high rate of early
coronary reperfusion achieved with various thrombolytic
agents, reocclusion of the infarct-related artery and subse-
quent recurrent ischemia remain the "stumbling blocks" of
this therapy. It is currently reported that either streptokinase
or recombinant tissue-type plasminogen activator (rt-PA)
therapy results in a rate of coronary reocclusion of 5% to
45% and a rate of recurrent angina of ::;50%. A recent study
(2) showed that early coronary reocclusion after thromboly-
sis was associated with an increase in mortality and a
worsening of regional myocardial function compared with
that in an infarct-related artery that did not reocclude. The
determinants of reocclusion are still uncertain. The degree of
residual coronary stenosis or the presence of an intraluminal
thrombus has been considered predictive of further reocclu-
sion, but this remains controversial (3).
Surprisingly, only one recent study (4) has prospectively
evaluated the effect of antiplatelet therapy on coronary
reocclusion. Unfortunately, the statistical power of the
Heparin-Aspirin Reperfusion Trial (HART) did not allow the
determination of the effect of aspirin on late reocclusion of
the infarct-related artery after thrombolysis. In the present
study, we evaluated a possible beneficial effect of aspirin in
coronary thrombolysis by performing a meta-analysis of the
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treated with aspirin was 11%compared with 25% in 513 patients
without aspirin therapy (p < 0.001). Recurrent ischemic events
were present in 25% of 2,977 patients treated with aspirin and
41 % of 721 patients treated without aspirin (p < 0.001). The effect
of aspirin was similar in trials with either streptokinase or
recombinant tissue.type plasminogen activator (rt-PA). Thus,
aspirin in the presence of heparin might prevent coronary reoc-
clusion after thrombolysis.
(J Am Coll CardioI1992;19:671-7)
clinical or angiographic outcome, or both, of studies with
and without aspirin in the thrombolysis protocol (4). Reoc-
clusion was assessed directly in 932 patients on late coronary
angiography. The occurrence of recurrent angina suggesting
acute episodes of reocclusion was analyzed in 3,698 patients.
Methods
Reported studies were selected with regard to their meth-
ods and end points, not to their results. Search and selection
of papers were undertaken according to previously de-
scribed guidelines for meta-analysis (5). Studies were iden-
tified by a computerized MEDLINE search from the year
1980 to 1990 of the references quoted in all identified articles
and abstracts. The MEDLINE search used "myocardial
infarction," "angiography," "thrombolytic therapy," "strep-
tokinase" and "plasminogen activator" as keywords. Only
articles published in peer-reviewed medical journals were
retained. No abstracts were used.
Study selection. The studies analyzed included patients
who had both successful coronary thrombolysis as proved
by angiography and later reevaluation before hospital dis-
charge with repeat coronary angiography. Studies in which
angiography was not performed but the in-hospital recur-
rence of ischemia was carefully reported were also included.
We retained studies in which patients had acute myocardial
infarction and thrombolysis was performed within 6 h after
the onset of pain by streptokinase or recombinant tissue-
type plasminogen activator (rt-PA). Patients who underwent
invasive systematic recanalization of the infarct-related ar-
tery (percutaneous transluminal coronary angioplasty or
coronary aortic bypass grafting) during the hospital course
were excluded. The studies with angiography included in
their protocol an early coronary angiogram 90 min after the
0735-1097/92/$5,00
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start of administration of the thrombolytic agent and one
predischarge additional angiogram obtained 8 to 14 days
later. Reocclusion was said to occur when an infarct-related
artery was occluded (Thrombolysis in Myocardial Infarction
Trial [TIMI] grade 0or 1) on the predischarge angiogram but
patent (TIMI grade 2 or 3) on the angiogram performed
90 min after initiation of thrombolysis.
Reocclusion rate evaluation. The reocclusion rate was
assessed either by reocclusion rates averaged over all the
studies or by the ratio of the total number of reoccluded
infarct-related arteries to the total number of reassessed
infarct-related arteries that were patent on the first angio-
gram (total reocclusion rate). We also made a high estimate
of the reocclusion rate for the following reasons. In some
studies that did not include a prethrombolysis angiogram,
the real reperfusion rate could not be assessed. This lack of
information led to an abnormally high patency rate after
thrombolysis because all vessels patent before therapy were
included in the patency evaluation. Because vessels patent
before therapy rarely reocclude, they were excluded from
our high estimate of reocclusion. In these particular studies,
we assumed the patency rate before thrombolysis to be 20%.
We also assumed that early deaths or emergency procedures
accompanied infarct-related artery reocclusion.
We estimated a high reocclusion rate by the following
equation: (Nr + Nd + Ne)/Nt (l - 0.2), where Nr = the
number ofpatients with a reoccluded infarct-related artery at
follow-up angiography; Nd =the number ofdeaths; Ne =the
number of patients with an emergency procedure; and Nt =
the number of reassessed infarct-related arteries at follow-up
angiography that were patent on the first angiogram. The
number of infarct-related arteries patent before thrombolysis
was approximated by 0.2 Nt. Thus, when possible, we
determined a reocclusion rate based only on angiographic
findings and another based on the clinical outcome.
Clinical data. Demographic data including age, gender,
prior myocardial infarction and location of the infarct were
collected. Incidence of heart failure at admission and early
ejection fraction obtained by angiography, when mentioned,
were also collected. Antithrombotic therapy (namely, the
total amount of heparin administered during the hospital
course and the daily dosage of aspirin) and the dosage and
mode of administration of the thrombolytic agent intrave-
nous or intracoronary were also evaluated. Adjunctive ther-
apy (that is, beta-adrenergic blocking agents, calcium chan-
nel blocking agents and nitrates) was not taken into account
because details of such therapy were rarely provided.
When necessary, additional information was retrieved
from previous related reports. We also looked for missing
data from patients in whom thtombolysis was proved suc-
cessful on the first angiogram and who were not reevaluated
later. A questionnaire was mailed to all the investigators of
studies with such patients who did not specify the reasons
for the lack of reevaluation, but few relevant data were
obtained. These reasons might have included death, clinical
deterioration related to the initial infarct, emergency proce-
dures (coronary angioplasty, coronary aortic bypass graft),
patient refusal (related or not to a putative reocclusion) or
other factors.
Patient outcome was assessed by 1) the time elapsed from
the onset of symptoms to therapy; 2) the rate of spontaneous
reperfusion or the rate of patency of the infarct-related
artery on the first angiogram performed before thrombolytic
therapy; 3) the patency rate of the infarct-related artery
90 min after initiation of therapy; 4) the plasma fibrinogen
level expressed as the ratio of the smallest measured con-
centration of plasma fibrinogen to prethrombolysis values;
5) the rate of bleeding complications defined by any kind of
significant bleeding except groin hematomas induced by
catheters or small bruising; and 6) the residual stenosis,
when specified at follow-up angiography, estimated by the
average of the percent reduction in vessel diameter of all
vessels with successful thrombolysis.
Recurrent ischemia was variably defined according to the
studies. We collected, when mentioned, the rate of in-
hospital episodes of angina pectoris without new docu-
mented myocardial infarction.
The type ofstudy design (namely, randomized or nooran-
domized) was also taken into account. Because randomiza-
tion was performed without regard to aspirin treatment, we
also included nonrandomized studies if they fulfilled the
inclusion criteria.
Statistical methods. The main goal of the statistical anal-
ysis was the evaluation of the effect of aspirin as adjunctive
treatment on the rate of coronary reocclusion after throm-
bolysis. The analysis was based on published information
and. following the methodology of meta-analysis (5,6), the
study was the sampling unit. The first assumption of our
analysis was the following:
The allocation of the treatment of interest (that is, the
presence or absence of aspirin) in a study could be consid-
ered as a random allocation, thereby assuming that a possi-
ble selection bias in the published studies did not affect the
allocation mechanism of aspirin and that all factors that
could additionally influence the probability of reocclusion
were well balanced between the two groups of studies. This
assumption is justified in the Discussion section.
The second assumption is expressed by the followint
model equation for the reocclusion rate: RRs T' observed in
study S, belonging to treatment group T (T = aspirin or
nonaspirin); and RRTS = fNr + aT.S + cT,S' where fNr is the
expected reocclusion rate with treatment T, aT,S is a true
deviation of the reocclusion rate from /kr in study S, and CT,S
is the measurement error in study S.
A random effect model was used for the aT,S' assuming
that the probabilities (fNr + au) are beta-distributed (7). The
measurement errors cT,S are distributed according to the
binomial distributions B(NTs, fNr + aT,S), where NTS is the
number of patients in study S.
Calculation ofa confidence interval for the risk difference
fLaspirin - fLnonaspirin was done by maximization of the
corresponding likelihood function and using the normal
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Table 1. Demographic Variables in the Presence or Absence of
Aspirin (ASA)
No. of Age Male Prior MI Ant MI CHF EF
Patients (yr) (%) (%) (%) (%) (%)
WithASA 3,209 56 ± 2 82 ± 8 13 ± 4 54 ± 18 14 ± 5 49 ± 4
(13) (12) (12) (9) (II) (4) (9)
Without 1,721 56 ± 3 79 ± 6 16 ± 6 50 ± 14 16 ± 9 48 ± 5
ASA (22) (20) (17) (9) (19) (6) (16)
Values are mean values ± SD. Numbers in parentheses represent the
number of groups with available data. Ant =anterior wall; CHF =percent of
patients with heart failure at admission; EF =ejection fraction determined by
angiography; MI = myocardial infarction.
distribution approximation for the estimation of the variance
(8).
To illustrate the strength of the model dependence of this
result, two alternative and more simple calculations were
done, each corresponding to a special simplification of the
model:
1) Study pooling: Under the assumption that all patients in
the same treatment group could be pooled ignoring study
effects, a confidence interval for the aspirin effect was
calculated from the resulting fourfold table.
2) Bootstrapping: The difference in the group mean reocclu-
sion rates was calculated for each of 10,000 bootstrap
samples drawn from the observed reocclusion rates (9).
Using the unweighted group mean values each time, this
corresponded to the assumption that study effects were
dominant compared with the measurement errors within
studies. From the 10,000 differences, a 95% confidence
interval could be obtained by the 2.5th and the 97.5th
percentiles. We used bootstrapping to allow for deviation
of normal distribution as well as for unequal variances
within groups.
Unless otherwise indicated, all values are expressed as
mean values ± SD.
Results
Study selection. From the 99 reports initially retrieved, 67
had to be rejected because of absence of angiography (n ==
13), no early angiography (n == 4), no late angiography (n ==
18), angiography performed after 1month (n == 5), coronary
angioplasty (n == 15), thrombolytic agent other than strep-
tokinase or rt-PA (n == 4), antiplatelet therapy left to the
discretion of the physicians (n == 2). Six reviews were also
discarded. From the 32 retained studies, 25 fulfilled all
angiographic criteria mentioned previously. The remaining
seven studies, although they did not include late angiogra-
phy, were analyzed separately because in-hospital recurrent
ischemia was carefully reported.
The 32 studies included 4,930 patients who could be
analyzed for either early recurrent ischemia (n == 3,698) or
reocclusion (n == 932). The 32 studies included 19 random-
ized and 13 nonrandomized studies, but randomization was
never related to the use of aspirin. Nonrandomized studies
presented the same clinical characteristics as the random-
ized studies; however, the spontaneous reperfusion rate was
significantly lower (14.4% vs. 23.3%, p < 0.01) despite
comparable time to treatment and thrombolytic regimen.
Studies differed mainly in the number of patients included.
All except two studies included heparin in their protocol.
Studies with and without aspirin (Tables 1 to 3). Among
these studies (10-42), 35 different groups of patients were
distinguished; 22 groups, with 1,721 patients, were not
treated with aspirin (10-30) and 13 groups, with 3,209
patients, were treated with aspirin (31-42). The median year
of study publication was 1986 (range 1981 to 1989) in both the
aspirin and nonaspirin groups. Streptokinase (either intra-
coronary or intravenous) was used in 24 groups and rt-PA in
11. The number of randomized groups was comparable in
groups using streptokinase or rt-PA. The groups were com-
parable with respect to demographic data and the dosage of
heparin and streptokinase (Tables 1 and 2). Time to treat-
ment, spontaneous reperfusion, fibrinogen levels and bleed-
ing complications were comparable (Table 3). The patency
rate after thrombolysis tended to be higher in the aspirin
group (72% vs. 63%, p == 0.05), but an important heteroge-
neity was found in patency rates because of substantial
differences in the thrombolytic regimen and protocol used.
Despite heterogeneity, the patency rate was inversely cor-
related to the time to treatment (r == -0.42, p < 0.01).
Table 2. Treatment Characteristics in the Presence or Absence of Aspirin (ASA)
Time to Rx ASA Heparin rt-PA STK (lC) STK (IV)
(h) (mg) (IU x W) (mg) (millions ofIV) (millions of IV)
With ASA 4.0 ± 1.3 326 ± 245 203 ± 0.9 150 ± 0 0.24 ± 0.01 1.3 ± OJ
(9) (13) (13) (4) (7) (3)
Without ASA 4.2 ± 1.1 0 2.8 ± 0.5 74 ± 15 0.22 ± 0.05 1.5 ± 0
(20) (22) (20) (7) (10) (5)
Values are mean ± SD. Numbers in parentheses represent the number of groups with available data. rt·PA =
recombinant tissue-type plasminogen activator; STK (IC) = total amount of intracoronary streptokinase; STK (IV)
= total amount of intravenous streptokinase; Time to Rx = time elapsed between the onset of chest pain and the
beginning of thrombolysis.
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Table 3. Initial Thrombolysis Outcome, Fibrinogen Decrease
and Bleeding Complications in the Presence or Absence of
Aspirin (ASA)
'p = 0.05. Values are mean ± SO. Numbers in parentheses represent the
number of groups with available data. Bleeding = percent of patients with
bleeding complications; Fibrinogen = ratio of the smallest measured concen-
tration of plasma fibrinogen to pretreatment values; Patency = percent
patency of the infarct-related artery 90 min after initiation of thrombolysis;
Spont Reperf = percent of patients with a patent infarct-related artery before
thrombolysis.
Reocclusion rate and recurrent ischemia (Tables 4 to 6).
Data on reocclusion were available in 932 patients (aspirin
group == 419 patients, group without aspirin == 513 patients);
all had predischarge angiography. The most striking result
was that groups treated with aspirin had a dramatically lower
reocclusion rate averaged over studies than did groups
without aspirin (11 % SEM == 1.2% vs. 29% SEM == 5%, p <
0.001) (Fig. I) and when the high estimated reocclusion rate
was considered, it still remained in favor of aspirin (15%
SEM == 2.1% vs. 34% SEM == 5%, p < 0.001). The estimated
risk difference (%) of reocclusion rate calculated by the
random effect, study pooling and bootstrapping methods led
to the same conclusion (Table 4). The same finding was
obtained when streptokinase and rt-PA groups were ana-
lyzed separately (Table 5). The total reocclusion rate was
also lower in groups treated with aspirin (11 % [45 of 419] vs.
25% [128 of 513], p < 0.001).
The daily dosage of aspirin varied from 80 to 1,000 mg,
but no correlation was found between this dosage and the
coronary reocclusion rate. No heterogeneity for the reocclu-
sion rate was found in the group treated with aspirin,
whereas slight quantitative heterogeneity was found in the
group without aspirin, which disappeared when one small
study was withdrawn from evaluation; this study (28) some-
what overestimated the reocclusion rate in this group. The
percent of missing data for reocclusion and residual stenosis
was comparable in the two groups. Recurrent ischemia was
lower in the group treated with aspirin (28% SEM == 2.8 vs.
45% SEM == 3.7%, p < 0.001) (Table 6).
With ASA
Without ASA
Spont Reperf
(%)
21 ± II
(8)
18 ± 7
(14)
Patency
(%)
72 ± 12'
(12)
63 ± 13
(20)
Fibrinogen
(%)
58 ± 26
(4)
56 ± 23
(II)
Bleeding
(%)
21 ± 13
(9)
23 ± 9
(15)
Mortality data were missing in eight and three groups
with and without aspirin, respectively, and were heteroge-
neous in their evaluation. There was a trend toward a lower
mortality rate in the aspirin group (5.8% vs. 7.3%, p == 0.09).
The group treated with aspirin had a higher dosage of
rt-PA (150 vs. 74 mg). The average dosage of streptokinase
was comparable in the two groups, but the reocclusion rate
was lower in the group treated with aspirin (11 % vs. 24%,
p < 0.01). Moreover, the effect of the dosage of streptoki-
nase on the reocclusion rate was examined in the aspirin and
nonaspirin groups, but no effect could be detected.
Discussion
Role of aspirin in reocclusion. The present study strongly
suggests that aspirin dramatically reduces both reocclusion
of the infarct-related coronary artery after successful throm-
bolysis and the incidence of in-hospital recurrent ischemia,
which is the clinical counterpart of recurrent coronary
reocclusion. Such periods of recurrent occlusion have been
documented (43) during early cardiac catheterization in
patients undergoing intracoronary thrombolysis with strep-
tokinase.
It is usually stated that the range of reocclusion rates after
thrombolysis is between 5% and 45%, depending on the
study considered. Various attempts have been undertaken to
find predictive variables offurther reocclusion and recurrent
ischemic events after thrombolysis, but no angiographic
variable (degree of residual stenosis, presence of an intralu-
minal thrombus) has proved successful (3). Our data show
that the reocclusion rate in the aspirin group was about 12%,
whereas in the nonaspirin group it was >25%. We retrieved
all factors that could additionally influence the probability of
reocclusion. Because these factors were similarly distributed
in the two groups, it seemed reasonable to assume that they
were in fact not correlated with the administration of aspirin
and could be ignored when comparing the two groups.
However, the studies with aspirin were associated with a
higher dosage of rt-PA; therefore, we cannot rule out the
possibility that the dosage of rt-PA influenced further reoc-
clusion even though the effect ofaspirin was still clearly seen
in studies in which streptokinase was the thrombolytic
agent.
Limited data are available on the clinical effects of
aspirin on late coronary reocclusion after thrombolysis. One
Table 4. Estimated Risk of Coronary Reocclusion After Thrombolysis Without and With Aspirin
Random effect model
Study pooling'
Bootstrap method'
Risk of Reocclusion
Without Aspirin (%)
(95% CI)
23.3 (19.3, 27.3)
25.0 (21.4,29.0)
2.84 (22.6, 35.7)
Risk of Reocclusion
With Aspirin (%)
(95% CI)
11.8 (7.7, 15.9)
10.7 (8.7, 15.3)
11.2 (7.7,14.0)
% Risk Difference
(RRnonasP,rin - RRaspmn)
(95% CI)
11.5 (5.5, 17.5)
14.2 (9.2, 19.2)
17.3 (10.7, 25.0)
'See Statistical methods. CI = confidence interval; RR = reocclusion rate.
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Figure 1. Reocdusion rate after thrombolytic therapy of the infarct-
related coronary artery among studies without and with aspirin
(ASA). The graph separates the results of randomized (random) and
nonrandomized (non random) studies. Each number (duplic~te or
not) corresponds to the reference quoted in the References section.
The mean (averaged over studies) ± SD is shown (p < 0.001).
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streptokinase without aspirin) would have introduced an-
other bias by mixing recent and "historical" studies, the
latter belonging to an outdated period. The similar dates of
publication of our studies show that the patients we were
studying had been treated within the same time interval. The
presence or absence of aspirin was probably not affected by
the bias of unpublished negative studies because the original
aim of the individual studies was completely unrelated to the
aim of our meta-analysis. Accordingly, these studies mostly
compared various thrombolytic therapies or strategies and
their respective reperfusion rates. For this reason, we also
retrieved studies that were not randomized because they
also fulfilled our selection criteria.
In addition, we selected certain studies in which invasive
treatment (angioplasty) was compared with conservative
treatment after thrombolysis. Such studies, although ran-
domized, included only patients who were eligible for either
treatment and excluded all other patients who could have
benefited from thrombolysis alone.
Heterogeneity in the study design. We restricted our
choice to studies in which patients were likely to be compa-
rable both in their treatment and their investigation time
frame. We excluded studies with too early reassessment of
coronary patency «48 h) because there are reasons to
believe that reocclusion can occur during the 1st week after
thrombolysis. We also excluded the study of Simoons et al.
(38) even though it included 184 patients with angiographic
data because early angiographic results were lacking. Inter-
withASAnoASA
Missing Data Residual Stenosis Angina
(%) (%) (%)
WithASA 19.4 ± 19.9 71 ± 11 28 ± 12"
(8) (5) (8)
Without ASA 19.6 ± 16.4 80 ± 7 45 ± 11
(18) (8) (8)
Streptokinase rt-PA
Reoccluded Patent Reoccluded Patent
IRA IRA IRA IRA
ASA 22 (11%) 175 ASA 23 (10%) 199
(n = 197) (n=222)
NoASA 81 (24%) 253 NoASA 47 (26%) 132
(n = 334) (n = 179)
Table 6. Late Angiographic Outcome and In-Hospital Recurrent
Angina in the Presence or Absence of Aspirin (ASA)
*p < 0.001. Values are mean ± SO. Numbers in parentheses represent the
number of groups with available data. Angina = in-hospital recurrent angina
pectoris; Missing Data = see Methods for definition; Residual Stenosis =
percent diameter reduction of the infarct-related artery assessed at follow-up
angiography.
report (44) states that aspirin does not influence early reper-
fusion in acute myocardial infarction. The recent HART
study (4) lacked sufficient statistical power to find a differ-
ence in late reocclusion when heparin and aspirin as adjunc-
tive therapy to rt-PA were compared. The most comprehen-
sive data on the effects of aspirin in thrombolytic therapy
come from the Second International Study of Infarct Sur-
vival (ISIS-2) (1), which showed that aspirin decreases the
early mortality rate in myocardial infarction and its effects
are additive to the effects of streptokinase. Because the
survival curves from the ISIS-2 trial show that the greatest
beneficial effect of aspirin is obtained during the 1st 3weeks
after treatment and because there is recent evidence (2) to
indicate that early reocclusion is associated with an increase
in the early mortality rate, it is tempting to conclude that
aspirin decreases early reocclusion. However, ISIS-2 and its
predecessor ISIS-l did not address the question of reocclu-
sion after thrombolysis.
Yet, one must be aware that the interpretation of a
meta-analysis should be made with caution. Comparing
reocclusion rates in the current published reports is danger-
ous for the following reasons.
Selection bias. Bias in the selection of studies constitutes
the greatest shortcoming of meta-analyses because unpub-
lished negative studies create a bias toward positive results.
We cannot claim that our selection of studies represents the
exhaustive bulk of work published in the thrombolysis era.
However, trying to include the oldest and preliminary stud-
ies (which would have given more weight to studies with
Table S. Reocduded Infarcted-Related Artery (IRA) at Follow-Up
Angiography in Studies With Streptokinase or Recombinant
Tissue-Type Plasminogen Activator (rt-PA) in the Presence or
Absence of Aspirin (ASA)
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estingly, that study (38) included aspirin in its protocol and
showed a late coronary occlusion rate of 11%, which is
consistent with our results and those of a recent survey (2)
that found a reocclusion rate of 12% among 713 patients
reevaluated after treatment with rt-PA or urokinase in asso-
ciation with aspirin.
Random presence of aspirin. Because nothing is known
about the reason for the presence or absence of aspirin in the
treatment, as is the case for noncontrolled adjunctive ther-
apy (nitrates, beta-blockers), a hidden reason could have
introduced a bias whose direction is not known. In addition,
the absence of aspirin in the protocol does not preclude the
possibility that a substantial number ofpatients (20% accord-
ing to certain studies [2]) were already treated with aspirin.
If this was the case, this uncontrolled treatment with aspirin
would have unexpectedly protected patients in the nonaspi-
rin group against reocclusion and thereby we might have
underestimated the true reocclusion rate in the absence of
aspirin.
Missing prethrombolysis angiograms. Pooling studies
with and without prethrombolysis angiography has draw-
backs. Only studies with prethrombolysis angiography can
reliably assess the reocclusion rate. However, all available
studies showed very similar spontaneous reperfusion rates
before thrombolysis and this enabled us to estimate that in
approximately 20% of patients with only postthrombolysis
angiography, the infarct-related artery was already reper-
fused before thrombolysis. Because patients whose artery
reperfused spontaneously were unlikely to exhibit reocclu-
sion, we made the assumption that 20% of the patients with
late angiography belonged in this category and were thus
withdrawn from the estimate of the "high" reocclusion rate.
When the number of early deaths and of patients undergoing
emergency procedures were added to the number of patients
proved by late angiography to have had reocclusion, the new
estimate of reocclusion rate was still strongly in favor of
aspirin.
Conclusions. Although a study based on meta-analysis
cannot precisely quantify in a confirmative manner the effect
of aspirin in reducing coronary reocclusion, there is over-
whelming evidence that aspirin in the presence of heparin
reduces late reocclusion and recurrent ischemia after throm-
bolysis. We speculate that this effect may account for the
beneficial effect of aspirin on the mortality rate associated
with acute coronary thrombolysis. How more potent an-
tithrombotic compounds than aspirin would further reduce
early coronary reocclusion and recurrent ischemia remains
to be determined.
We thank Stephan Laage, PhD for calculating the random effect model and
Mimi Lobsiger for typing the manuscript.
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